The European Medicines Agency is inviting stakeholder feedback on what might be considered good practice for collecting high quality data from patient disease registries, and the factors that should be considered for undertaking registry studies to support regulatory decision-making.
The EMA's proposals are outlined in a draft discussion paper that mainly focuses on patient disease registries, although many of its considerations can also be applied to product registries...